Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Calcifediol | 1 | 2013 | 15 | 0.480 |
Why?
|
Cholecalciferol | 1 | 2013 | 46 | 0.470 |
Why?
|
Janus Kinases | 1 | 2012 | 174 | 0.400 |
Why?
|
Idarubicin | 1 | 2011 | 446 | 0.350 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2013 | 6884 | 0.330 |
Why?
|
Blood Group Incompatibility | 1 | 2008 | 34 | 0.320 |
Why?
|
Anemia, Hemolytic | 1 | 2008 | 53 | 0.310 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2011 | 726 | 0.310 |
Why?
|
Muscular Diseases | 1 | 2006 | 161 | 0.260 |
Why?
|
Cytarabine | 1 | 2011 | 1971 | 0.260 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 1298 | 0.260 |
Why?
|
Steroids | 1 | 2006 | 354 | 0.250 |
Why?
|
Immunologic Factors | 1 | 2008 | 649 | 0.240 |
Why?
|
B-Lymphocytes | 1 | 2008 | 1292 | 0.210 |
Why?
|
MicroRNAs | 1 | 2013 | 2943 | 0.180 |
Why?
|
Obesity | 1 | 2011 | 2910 | 0.170 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8869 | 0.150 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 2793 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2014 | 15806 | 0.140 |
Why?
|
Graft vs Host Disease | 1 | 2006 | 2620 | 0.130 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 4351 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 1 | 2010 | 4752 | 0.130 |
Why?
|
Signal Transduction | 1 | 2012 | 11962 | 0.120 |
Why?
|
Receptors, Calcitriol | 1 | 2013 | 134 | 0.110 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2008 | 6518 | 0.110 |
Why?
|
STAT Transcription Factors | 1 | 2012 | 79 | 0.110 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 865 | 0.090 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 560 | 0.090 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2011 | 603 | 0.080 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 561 | 0.080 |
Why?
|
ABO Blood-Group System | 1 | 2008 | 127 | 0.080 |
Why?
|
Rituximab | 2 | 2014 | 1527 | 0.080 |
Why?
|
Lymphoma, B-Cell | 1 | 2014 | 893 | 0.080 |
Why?
|
Aged | 6 | 2014 | 69889 | 0.070 |
Why?
|
Stem Cell Transplantation | 2 | 2010 | 1360 | 0.070 |
Why?
|
Aged, 80 and over | 4 | 2014 | 29820 | 0.070 |
Why?
|
Imatinib Mesylate | 1 | 2010 | 1664 | 0.070 |
Why?
|
Methylprednisolone | 1 | 2006 | 193 | 0.070 |
Why?
|
Myeloproliferative Disorders | 1 | 2012 | 766 | 0.070 |
Why?
|
Transplantation, Homologous | 2 | 2009 | 2846 | 0.070 |
Why?
|
Benzamides | 1 | 2010 | 1830 | 0.060 |
Why?
|
Transcriptome | 1 | 2013 | 1863 | 0.060 |
Why?
|
Myelodysplastic Syndromes | 2 | 2009 | 2970 | 0.060 |
Why?
|
Neoplasm, Residual | 1 | 2010 | 1654 | 0.060 |
Why?
|
Syndrome | 1 | 2008 | 1355 | 0.060 |
Why?
|
Blood Transfusion | 1 | 2008 | 582 | 0.060 |
Why?
|
Databases, Factual | 1 | 2011 | 2202 | 0.060 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2008 | 426 | 0.060 |
Why?
|
Body Mass Index | 1 | 2011 | 2207 | 0.060 |
Why?
|
Treatment Outcome | 3 | 2014 | 32747 | 0.060 |
Why?
|
Adult | 5 | 2014 | 77741 | 0.060 |
Why?
|
Middle Aged | 5 | 2014 | 85935 | 0.050 |
Why?
|
Humans | 9 | 2014 | 260343 | 0.050 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 2390 | 0.050 |
Why?
|
Piperazines | 1 | 2010 | 2098 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 4543 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 6212 | 0.050 |
Why?
|
Disease Progression | 1 | 2012 | 6680 | 0.050 |
Why?
|
Leukemia, Myeloid | 1 | 2006 | 940 | 0.050 |
Why?
|
Acute Disease | 1 | 2006 | 2412 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2014 | 37730 | 0.050 |
Why?
|
Female | 5 | 2014 | 141542 | 0.050 |
Why?
|
Prognosis | 2 | 2013 | 21668 | 0.040 |
Why?
|
Male | 4 | 2014 | 122669 | 0.040 |
Why?
|
Pyrimidines | 1 | 2010 | 3515 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 5179 | 0.040 |
Why?
|
Young Adult | 2 | 2014 | 21357 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 9982 | 0.030 |
Why?
|
Adolescent | 2 | 2014 | 31121 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 125 | 0.030 |
Why?
|
Genes, bcl-2 | 1 | 2014 | 167 | 0.030 |
Why?
|
Genes, myc | 1 | 2014 | 358 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2014 | 9997 | 0.030 |
Why?
|
Bevacizumab | 1 | 2014 | 930 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2009 | 43 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 14259 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 502 | 0.020 |
Why?
|
Vidarabine | 1 | 2014 | 1341 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1245 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2009 | 533 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 3000 | 0.020 |
Why?
|
Recurrence | 1 | 2014 | 4731 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 4994 | 0.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2014 | 3236 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 2009 | 1959 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 4822 | 0.010 |
Why?
|
Cohort Studies | 1 | 2009 | 9230 | 0.010 |
Why?
|
Risk Factors | 1 | 2009 | 17503 | 0.010 |
Why?
|